コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 function in patients with moderate to severe diffuse scleroderma.
2 with a diagnosis of systemic sclerosis with diffuse scleroderma.
3 atients were classified as having limited or diffuse scleroderma according to standard definitions.
5 vation should lead to the early diagnosis of diffuse scleroderma and should identify patients at high
6 monstrated that the autoantigens targeted in diffuse scleroderma are unified by their enrichment in n
7 that several of the autoantigens targeted in diffuse scleroderma are uniquely susceptible to cleavage
8 patients with the chronic fibrotic disorder diffuse scleroderma [diffuse systemic sclerosis (dSSc)]
9 ction rubs and symptoms and signs typical of diffuse scleroderma, including more severe skin thickeni
10 ral history of changes in skin thickening in diffuse scleroderma is quite variable, but the significa
12 vement was assessed in 134 SSc patients with diffuse scleroderma (mean +/- SD disease duration of 10
13 ement were assessed in 134 SSc patients with diffuse scleroderma (mean +/- SD duration of SSc 10 +/-
14 evere organ involvement in SSc patients with diffuse scleroderma most often occurs early in the cours
15 ease expression with the majority exhibiting diffuse scleroderma, pulmonary fibrosis, and autoantibod
16 ng patients surviving the first few years of diffuse scleroderma, striking improvement in skin thicke
17 ften have certain features typically seen in diffuse scleroderma, such as pulmonary fibrosis and scle
18 mponents were more frequent in patients with diffuse scleroderma than in those with either the limite
19 t in the HAQ DI score in these patients with diffuse scleroderma was associated with improvement in s
20 -dose corticosteroids in patients with early diffuse scleroderma who are at increased risk of develop
23 eroderma Databank and included patients with diffuse scleroderma who were seen between January 1, 197
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。